Navigation Links
Bone Drugs May Beat Back Breast Cancer
Date:12/10/2009

Bisphosphonates seem to prevent recurrence, researchers find

THURSDAY, Dec. 10 (HealthDay News) -- Bone-building drugs used by tens of millions of women to fight osteoporosis also cut the risk of breast cancer, suggesting the drugs may play a dual role in keeping women healthy.

"Bone loss and potential fractures are a known complication of breast cancer therapy. Our feeling is that bisphosphonates may actually prevent disease recurrence through a variety of mechanisms," said Dr. Adam Brufsky, associate director of clinical investigation at the University of Pittsburgh Cancer Institute.

Brufsky authored one of several studies exploring the role of bone-building drugs in breast cancer prevention that were to be presented Thursday at the San Antonio Breast Cancer Symposium.

Bisphosphonates are already used to treat complications that result from breast cancer spreading to the bones.

One study looked at more than 150,000 postmenopausal women who participated in the U.S. government-led Women's Health Initiative (WHI).

The women taking bisphosphonates, namely Fosamax (alendronate), had a 32 percent reduction in their rate of invasive breast cancer compared to women who were not taking one of these drugs.

The University of California, Los Angeles, researchers were able to control for the fact that women with low bone mineral density are already at lower risk for breast cancer.

Because the study was not a randomized, controlled one, said lead investigator Dr. Rowan Chlebowski, a professor and medical oncologist with UCLA, "the findings are not definitive but they do provide a strong signal."

In another study, Israeli researchers found that postmenopausal women taking bisphosphonates for one or more years had a 29 percent reduction in their risk of breast cancer.

And the tumors that did appear tended to be estrogen receptor-positive and thus easier to treat than estrogen receptor-negative tumors.

And in other news from the symposium:

  • Researchers from the University of Pittsburgh Cancer Institute, led by Brufsky, concluded that zoledronic acid, another bisphosphonate, is safe and effective for use by postmenopausal women with breast cancer who are being treated with aromatase inhibitors. Bone mineral density increased 6.2 percent in women taking zoledronic acid, compared with 2.4 percent in the control group. Fractures were also reduced slightly in the treatment group, but it's unclear how significant this was. Zoledronic acid is marketed under several brand names, including Zometa.
  • A new drug, denosumab, a monoclonal antibody, performed better than zoledronic acid in easing problems associated with the spread of breast cancer to the bones.
  • A final study found that it was safe to give zoledronic acid to women with breast cancer being treated with the aromatase inhibitor Femara (letrozole) before surgery. No clear indication emerged as to whether the dual treatment was effective, however.

More information

The National Cancer Institute has more on breast cancer.



SOURCES: Dec. 9, 2009, teleconference with: Rowan Chlebowski, M.D., Ph.D., medical oncologist, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center, and Adam Brufsky, M.D., Ph.D., associate professor, medicine, associate chief, hematology-oncology, and associate director, clinical investigation, University of Pittsburgh Cancer Institute


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. AIDS Drugs Dont Need Routine Lab Monitoring
2. Statement of HDMA President and CEO John M. Gray on the Importation of Prescription Drugs
3. Case Western Reserve to receive $19.7m to study tuberculosis treatment drugs
4. OrderOnlineDrugs.com Makes Ordering Drugs Online Safe and Affordable
5. Second-line CML drugs evoke faster response than front-line therapy
6. Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy
7. Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
8. Diabetes Drugs Go Head-to-Head in Study
9. drugstore.com Continues Global Sales Expansion to More Than 3.5 Billion International Consumers
10. China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009
11. Coverage of inexpensive drugs may increase length and quality of life after heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... FL (PRWEB) , ... February 05, 2016 , ... ... the largest domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual ... awareness for kids and adults with muscular dystrophy, ALS and related diseases that ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President ... have signed a joint enrollment and degree completion agreement. The agreement, which ... baccalaureate degrees at FHU|Dickson. , The agreement allows students to be jointly ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official operators of ... direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque ... , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: each ... longer to access the treadmills. It’s a predictable trend. After the excesses of November ... get in shape by joining gyms, starting new walking or running routines, or signing ...
(Date:2/5/2016)... WA (PRWEB) , ... February 05, 2016 , ... ... firm, ranked #3 in the 2015 Best in KLAS: Software & Services for ... The annual Best in KLAS report independently ranks vendor performance by healthcare executives, ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)...  LivaNova, PLC, Hersteller des VNS-Therapie ® ... Titel „Epilepsy Around the World" (Epilepsie auf ... gegenüber ein größeres Bewusstsein gefördert werden soll ... Epilepsie auf dem Internationalen Epilepsietag zu einem ... der neuen Infografik sollen wichtige Statistiken zur ...
(Date:2/5/2016)... Calif. , Feb. 5, 2016  Syneron ... global aesthetic device company, announced today that ... Candela North America, is scheduled to participate in ... Healthcare Conference on February 11, 2016 in ... will allow institutional investors to meet with the ...
(Date:2/5/2016)... 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced ... ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of ... Tribute. The combined company will operate under Aralez Pharmaceuticals ... in Canada , Ireland ... . Under the terms of the Agreement and Plan ...
Breaking Medicine Technology: